BerGenBio narrows R&D to focus on NSCLC and Covid-19; Oral SERDs see another setback as G1 drops program
BerGenBio said it will prioritize its pipeline to focus on first-line non-small cell lung cancer and Covid-19 with its lead drug bemcentinib. That means work in acute myeloid leukemia, MDS and ovarian cancer has been put on pause.
The company said the narrowed R&D work provides the “optimal path towards translating BerGenBio’s strong scientific foundation” and the shift comes a month after the biotech named former IQVIA VP of oncology Cristina Oliva as its CMO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
